KTE-C19

August 3, 2017

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes

News

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain ... Read more

July 7, 2017July 7, 2017

Response to Kite’s CAR T-Cell Therapy in NHL Isn’t Dependent on Disease Factors, Researchers Say

News

The ZUMA-1 Phase 2 clinical trial of the CAR T-cell therapy axicabtagene ciloleucel (KTE-C19) showed that 82% of patients with treatment-resistant or relapsed aggressive non-Hodgkin’s lymphoma (NHL) responded to the ... Read more

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive non-Hodgkin’s ... Read more

March 17, 2017March 17, 2017

Kite’s CAR T-cell Therapy Helps Aggressive Lymphoma Patients, Clinical Trial Shows

News

Eighty-two percent of patients with refractory aggressive lymphoma have responded to Kite Pharma‘s KTE-C19 chimeric antigen receptor (CAR) T-cell therapy, and 36 percent have achieved complete remission, according to preliminary results of a clinical ... Read more

March 2, 2017

Kite’s CAR T-cell Therapy Could Markedly Benefit NHL Patients, ZUMA-1 Data Suggests

News

Kite Pharma‘s lead CAR T-cell therapy axicabtagene ciloleucel may be a promising therapeutic approach for patients with refractory, aggressive non-Hodgkin lymphoma (NHL), according to primary data from the ZUMA-1 Phase 1/2 ... Read more

January 9, 2017

New CAR T-cell Therapy Shows ‘Remarkable’ Promise for Highly Refractory Lymphoma

News

Patients with refractory diffuse large B-cell lymphoma (DLBCL) could greatly benefit from a new CAR T-cell therapy called KTE-C19, according to recently published data from the Phase 1 ZUMA-1 trial. ... Read more

January 6, 2017

Kite and Vitruvian Developing Platform to Safely Deliver T-cell Therapies at Commercial Scale

News

Kite Pharma and Vitruvian Networks announced a strategic collaboration to create a software solution that will help to support commercial availability of T-cell therapies. The companies will jointly design and develop a ... Read more

December 19, 2016

Kite’s CAR T-cell Therapy Shows Great Promise in Non-Hodgkin’s Lymphoma Patients

News

Car T-cell immunotherapy has shown great promise in non-Hodgkin’s lymphoma patients, according to data from a multicenter Phase 1/2 trial, presented at the 58th American Society of Hematology (ASH) Annual Meeting ... Read more

November 8, 2016

Trial Data on Kite’s Lead Candidate for B-Cell Lymphomas to Be Presented at Meeting

News

Kite Pharma will present data from multiple clinical trials of KTE-C19, the company’s lead candidate CAR-T cell therapy for B-cell lymphomas and leukemias at the American Society of Hematology (ASH) ... Read more